Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 3037-3047

  Kim, Michael H ^a   Lin, J ^b   Hussein, M ^c   Battleman, D ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SANOFI   (France)

^c IQVIA   (United States)

Author keywords

Adverse events; Atrial fibrillation; Cost; Managed care; Rate control; Rhythm control

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; DIGOXIN; DILTIAZEM; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; METOPROLOL; PROPAFENONE; PROPRANOLOL; QUINIDINE; SOTALOL; VERAPAMIL;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; ASTHMA; BRADYCARDIA; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DATA BASE; DISEASE CONTROL; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FUNCTION TEST; GASTROINTESTINAL DISEASE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INCIDENCE; INFORMATION SYSTEM; LIVER FUNCTION; LIVER TOXICITY; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONITORING; NEUROLOGIC DISEASE; OPTIC NEURITIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; QT PROLONGATION; RETROSPECTIVE STUDY; THYROID FUNCTION; TORSADE DES POINTES; VISION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; COHORT STUDIES; COST OF ILLNESS; DRUG MONITORING; DRUG TOXICITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 72549112116     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903368716     Document Type: Article

References (27)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
2. Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and co-morbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin 2005;21:1693-1699 (Pubitemid 41505035)
3. Coyne KS, Paramore C, Grandy S, et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 2006;9:348-356 (Pubitemid 44337788)
4. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354 (Pubitemid 44252297)
5. Product Information: Betapace™, sotalol hydrochloride. Bayer HealthCare Pharmaceuticals Inc., NJ, US. PI revised April 2007
6. Product Information: Cordarone®, amiodarone hydrochloride. Wyeth Laboratories, PA, US. PI revised August 20, 2001
7. Product Information: Rythmol®, propafenone hydrochloride. Reliant Pharmaceuticals, Inc., NJ, US
8. Product Information: Lopressor®, metoprolol tartrate. Novartis Pharmaceuticals Corporation, NY, US. PI revised February, 2008
9. Product Information: Lanoxin®, digoxin. GlaxoSmithKline, NC, US. PI revised November, 2006
10. Product Information: Cardizem®, diltiazem hydrochloride. Biovail Laboratories International SLR, ON, US. PI revised September, 2007
11. Kim MH, Klingman D, Lin J, et al. Cost of hospital admission for antiarrhythmic drug initiation in atrial fibrillation. Ann Pharmacother 2009;43:840-848
12. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920
13. Al-Khatib SM, LaPointe NM, Curtis LH, et al. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol 2003;91:91-94
14. Singh BN. Amiodarone: a multifaceted antiarrhythmic drug. Curr Cardiol Rep 2006;8:349-355
15. Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician 2003;68:2189-2196
16. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833 (Pubitemid 35417773)
17. Marshall DA, Levy AR, Vidaillet H, et al. Cost-effectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med 2004;141:653-661 (Pubitemid 39440011)
18. Hagens VE, Vermeulen KM, TenVergert EM, et al. Rate control is more costeffective than rhythm control for patients with persistent atrial fibrillation - results from the RAte Control versus Electrical cardioversion (RACE) study. Eur Heart J 2004;25:1542-1549 (Pubitemid 39165633)
19. Pietrasik A, Kosior DA, Niewada M, et al. The cost comparison of rhythm and rate control strategies in persistent atrial fibrillation. Int J Cardiol 2007;118:21-27 (Pubitemid 46517682)
20. Blumentals WA, Gomez-Caminero A, Joo S, et al. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004;16:350-353 (Pubitemid 39273762)
21. Kessler RC, Cantrell CR, Berglund P, et al. The effects of copayments on medication adherence during the first two years of prescription drug treatment. J Occup Environ Med 2007;49:597-609 (Pubitemid 46918851)
22. Kim MH, Lin J, Hussein M, et al. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Curr Med Res Opin 2009;25:1215-1220
23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383 (Pubitemid 17055592)
24. Burgess C, Blaikie A, Ingham T, et al. Monitoring the use of amiodarone: compliance with guidelines. Intern Med J 2006;36:289-293
25. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-1794 (Pubitemid 30954031)
26. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 2003;91:15D-26D (Pubitemid 36372060)
27. Van Gelder IC, Wyse DG, Chandler ML, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-942